# Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

> **NCT03841565** · PHASE2 · WITHDRAWN · sponsor: **Academic and Community Cancer Research United**

## Conditions studied

- Recurrent Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Daratumumab
- **DRUG:** Dexamethasone
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT03841565
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-08-07
- **Primary completion:** 2022-02-09
- **Final completion:** 2022-02-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** There are no patients enrolled on this study and all efforts are being discontinued.
- **Last updated:** 2022-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03841565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03841565, "Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03841565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*